The role of anticytokine therapy in heart failure: recent lessons from preclinical and clinical trials?

[1]  L. Old,et al.  Tumor necrosis factor (TNF). , 1985, Science.

[2]  K. Sliwa,et al.  Beneficial Effects of Pentoxifylline in Patients With Idiopathic Dilated Cardiomyopathy Treated With Angiotensin-Converting Enzyme Inhibitors and Carvedilol: Results of a Randomized Study , 2001, Circulation.

[3]  D. Wagner,et al.  AMPD1 gene mutation in congestive heart failure: new insights into the pathobiology of disease progression. , 1999, Circulation.

[4]  W. Colucci,et al.  Interleukin-1β and Tumor Necrosis Factor-α Decrease Collagen Synthesis and Increase Matrix Metalloproteinase Activity in Cardiac Fibroblasts In Vitro , 2000 .

[5]  Simon C Watkins,et al.  Negative inotropic effects of cytokines on the heart mediated by nitric oxide. , 1992, Science.

[6]  F. Breedveld,et al.  Functional Analysis of a Human Tumor Necrosis Factor α (TNF-α) Promoter Polymorphism Related to Joint Damage in Rheumatoid Arthritis , 1998, Molecular medicine.

[7]  L. Moldawer,et al.  Direct Evidence for Cytokine Involvement in Neointimal Hyperplasia , 2000, Circulation.

[8]  E. Vizi,et al.  Isoproterenol regulates tumour necrosis factor, interleukin‐10, interleukin‐6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia , 1997, Immunology.

[9]  F. Parhami,et al.  Tumor Necrosis Factor-&agr; Promotes In Vitro Calcification of Vascular Cells via the cAMP Pathway , 2000, Circulation.

[10]  G. Freeman,et al.  beta-adrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. , 2000, Circulation.

[11]  C. Perez,et al.  A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF , 1988, Cell.

[12]  M. Seishima,et al.  Tumor Necrosis Factor-α (TNF-α) Plays a Protective Role in Acute Viral Myocarditis in Mice , 2001 .

[13]  B. Beutler,et al.  A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. , 1993, The Journal of clinical investigation.

[14]  P. Zabel,et al.  OXPENTIFYLLINE IN ENDOTOXAEMIA , 1989, The Lancet.

[15]  K. Tracey,et al.  Peptide Regulatory Factors CACHECTIN/TUMOUR NECROSIS FACTOR , 1989, The Lancet.

[16]  Anita Deswal,et al.  Cytokines and Cytokine Receptors in Advanced Heart Failure: An Analysis of the Cytokine Database from the Vesnarinone Trial (VEST) , 2001, Circulation.

[17]  K. Sliwa,et al.  Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy , 1998, The Lancet.

[18]  A. Blakemore,et al.  Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. , 1992, Human molecular genetics.

[19]  B. Beutler,et al.  Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Duff,et al.  Genetics of tumour necrosis factor-alpha in autoimmune, infectious, and neoplastic diseases. , 1995, Journal of inflammation.

[21]  D. Mann,et al.  Effects of Tumor Necrosis Factor Gene Polymorphisms on Patients With Congestive Heart Failure , 1998 .

[22]  E. Thonar,et al.  Levels of circulating tumor necrosis factor alpha and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulfate. , 1993, Arthritis and rheumatism.

[23]  G. Noon,et al.  Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery. , 1999, Circulation.

[24]  J. Thornby,et al.  Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. , 1999, Journal of the American College of Cardiology.

[25]  H. Friedman,et al.  Tumor necrosis factor induction by Candida albicans from human natural killer cells and monocytes. , 1988, Journal of immunology.

[26]  W. Sandborn.  A controlled trial of anti-tumor necrosis factor alpha antibody for Crohn's disease. , 1997, Gastroenterology.

[27]  H. Oral,et al.  Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). , 1996, Journal of the American College of Cardiology.

[28]  G. MacGowan,et al.  Circulating interleukin-6 in severe heart failure. , 1997, The American journal of cardiology.

[29]  D. Mann,et al.  Soluble TNF binding proteins modulate the negative inotropic properties of TNF-alpha in vitro. , 1995, The American journal of physiology.

[30]  B. Chandrasekar,et al.  Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. , 2000, Circulation.

[31]  A. Feldman,et al.  Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. , 2000, The Journal of clinical investigation.

[32]  Yy Li,et al.  Matrix metalloproteinases in pathophysiology and treatment of heart failure , 2001, The Lancet.

[33]  M. Yacoub,et al.  Elevated Tumor Necrosis Factor-&agr; and Interleukin-6 in Myocardium and Serum of Malfunctioning Donor Hearts , 2000, Circulation.

[34]  T. van der Poll,et al.  Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. , 1996, The Journal of clinical investigation.

[35]  H. Fillit,et al.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.

[36]  S. Anker,et al.  Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure , 2000, Circulation.

[37]  A. Koretsky,et al.  Dilated Cardiomyopathy in Transgenic Mice With Cardiac-Specific Overexpression of Tumor Necrosis Factor-α , 1997 .

[38]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[39]  A. Matsumori,et al.  Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. , 1998, Circulation.

[40]  P. Ladenson,et al.  Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[41]  M. Zile,et al.  Matrix metalloproteinase inhibition during the development of congestive heart failure : effects on left ventricular dimensions and function. , 1999, Circulation research.

[42]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Feldman,et al.  Downregulation of Matrix Metalloproteinases and Reduction in Collagen Damage in the Failing Human Heart After Support With Left Ventricular Assist Devices , 2001, Circulation.

[44]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[45]  J. O’dell.  TNF-α Inhibition: The Need for a Tumor Necrosis Factor Thermostat , 2001 .

[46]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[47]  D. Wallach,et al.  Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. , 1992, The EMBO journal.

[48]  L. Vaca,et al.  Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. , 1993, The Journal of clinical investigation.

[49]  I. Komuro,et al.  Peroxisome Proliferator–Activated Receptor Activators Inhibit Lipopolysaccharide-Induced Tumor Necrosis Factor-α Expression in Neonatal Rat Cardiac Myocytes , 2000 .

[50]  F. Stüber,et al.  A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. , 1996, Critical care medicine.

[51]  C. Beaumont,et al.  Role for NF-κB in the Regulation of Ferritin H by Tumor Necrosis Factor-α (*) , 1995, The Journal of Biological Chemistry.

[52]  A. Matsumori,et al.  Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. , 1997, Circulation.

[53]  O. Febo,et al.  Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. , 1995, Circulation.

[54]  Simon C Watkins,et al.  Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[55]  T. Ohtsuka,et al.  Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. , 2001, Journal of the American College of Cardiology.

[56]  S. Reis,et al.  Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. , 2000, Journal of the American College of Cardiology.

[57]  M. Satoh,et al.  Expression of tumor necrosis factor-alpha--converting enzyme and tumor necrosis factor-alpha in human myocarditis. , 2000, Journal of the American College of Cardiology.

[58]  J. Woessner,et al.  Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. , 1996, The American journal of pathology.

[59]  Simon C Watkins,et al.  Mitochondrial Abnormalities in Tumor Necrosis Factor-&agr;–Induced Heart Failure Are Associated With Impaired DNA Repair Activity , 2001, Circulation.

[60]  A. Feldman,et al.  MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure. , 2002, American journal of physiology. Heart and circulatory physiology.

[61]  Simon C Watkins,et al.  Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. , 2001, American journal of physiology. Heart and circulatory physiology.

[62]  G. Schreiner,et al.  Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. , 1990, Circulation research.

[63]  H. Oral,et al.  Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. , 1997, Circulation research.

[64]  D. Wallach,et al.  Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. , 1990, The Journal of biological chemistry.

[65]  S. Watanabe,et al.  Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. , 1997, Pharmacology.

[66]  A. Peaceman,et al.  Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. , 1994, American journal of obstetrics and gynecology.

[67]  D. Mann,et al.  Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart , 1996 .

[68]  I. Wicks,et al.  Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. , 2001, The Journal of clinical investigation.

[69]  D. Mann,et al.  Nitric Oxide Provokes Tumor Necrosis Factor-&agr; Expression in Adult Feline Myocardium Through a cGMP-Dependent Pathway , 2000, Circulation.

[70]  B. Beutler,et al.  Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1 , 1986, The Journal of experimental medicine.

[71]  E. Nilsson,et al.  Isolation and characterization of a tumor necrosis factor binding protein from urine , 1989, European journal of haematology.

[72]  M. Seishima,et al.  Tumor necrosis factor-alpha (TNF-alpha) plays a protective role in acute viralmyocarditis in mice: A study using mice lacking TNF-alpha. , 2001, Circulation.

[73]  Gilla Kaplan,et al.  Selection of Novel Analogs of Thalidomide with Enhanced Tumor Necrosis Factor α Inhibitory Activity , 1996, Molecular medicine.

[74]  A. Feldman,et al.  Interleukin-1 beta inhibits phospholamban gene expression in cultured cardiomyocytes. , 1997, Circulation research.

[75]  A. Feldman,et al.  Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. , 1999, Cardiovascular research.

[76]  D. Fukai,et al.  Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. , 1998, Journal of the American College of Cardiology.

[77]  S. Basili,et al.  Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. , 2000, Journal of the American College of Cardiology.

[78]  J. Larrick,et al.  Cytotoxic mechanism of tumor necrosis factor‐α , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[79]  M. Lovett,et al.  CYTOKINE GENE EXPRESSION IN REJECTING CARDIAC ALLOGRAFTS , 1992, Transplantation.

[80]  M. R. Bergman,et al.  Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors. , 1996, The Journal of pharmacology and experimental therapeutics.

[81]  D. Grennan,et al.  Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. , 1995, Disease markers.

[82]  F. Clubb,et al.  Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. , 1998, Circulation.

[83]  J. Aliberti,et al.  Trypanosoma cruzi–Infected Cardiomyocytes Produce Chemokines and Cytokines That Trigger Potent Nitric Oxide–Dependent Trypanocidal Activity , 2000, Circulation.

[84]  M. Entman,et al.  Tumor Necrosis Factor-α Provokes a Hypertrophic Growth Response in Adult Cardiac Myocytes , 1997 .

[85]  T. Mak,et al.  Low-molecular-weight tumor necrosis factor receptor p55 controls induction of autoimmune heart disease. , 1997, Circulation.

[86]  P. Robbins,et al.  Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. , 2000, Circulation.

[87]  J. Vilček,et al.  Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions. , 1991, The Journal of biological chemistry.

[88]  A. Demetris,et al.  Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. , 1997, Journal of cardiac failure.

[89]  P. Vassalli,et al.  The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.

[90]  P. Robbins,et al.  Adenoviral-directed overexpression of soluble tumor necrosis factor receptors reverses myocarditis in transgenic mice with congestive heart failure , 1998 .

[91]  A. Matsumori,et al.  Amiodarone inhibits production of tumor necrosis factor-alpha by human mononuclear cells: a possible mechanism for its effect in heart failure. , 1997, Circulation.

[92]  G Baumgarten,et al.  Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[93]  G. Schreiner,et al.  Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[94]  B. Beutler,et al.  Unraveling function in the TNF ligand and receptor families. , 1994, Science.

[95]  A. Feldman,et al.  Anti–Tumor Necrosis Factor-&agr; Antibody Limits Heart Failure in a Transgenic Model , 2001, Circulation.

[96]  M. Kinoshita,et al.  Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. , 2000, Journal of the American College of Cardiology.

[97]  J. Sadoshima.  Cytokine actions of angiotensin II. , 2000, Circulation research.

[98]  M. Entman,et al.  Decreased Expression of Tumor Necrosis Factor-&agr; and Regression of Hypertrophy After Nonsurgical Septal Reduction Therapy for Patients With Hypertrophic Obstructive Cardiomyopathy , 2001, Circulation.

[99]  R. Gentz,et al.  Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. , 1990, Cytokine.